Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

of marketing authorization approval from the European Commission for the use of pirfenidone for the treatment of IPF and the expected timing thereof, statements regarding commercial launch preparations and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, (i) whether the European Commission approves the marketing authorization for pirfenidone for the treatment of IPF and the actual timing of the decision; (ii) risks related to unexpected regulatory actions or delays or government regulation generally; (iii) risks related to the clinical and regulatory process for pirfenidone, including having no unexpected safety, toxicology, clinical or other issues; (iv) unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; (v) government, industry and general public pricing pressures; (vi) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections; (vii) risks related to building the infrastructure required for commercial launch in various countries in the European Union, and (viii) those other factors discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2010 (the "Form 10-K"), and other periodic reports filed with the SEC.  The risks and other factors discussed above should be considered only
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 28 US Oncology, Inc. will announce its financial results ... 7, 2009.A conference call and simultaneous webcast will be hosted ... earnings release. Additional information will be available on the company,s ... Room on the day of the earnings announcement. US/Canada Dial-in ...
... prove efficacious for both prophylactic and therapeutic ... (NYSE AMEX: CVM ) announced ... vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope ... induce protection against illnesses such as swine ...
... ST. LOUIS, April 28 Sigma-Aldrich (Nasdaq: ... esiRNA, a pool of gene-specific siRNA that provides a novel ... traditional synthetic RNAi, esiRNA ( http://www.sigma.com/esirna ... single gene target. This new tool is designed to eliminate ...
Cached Biology Technology:US Oncology to Report 2009 First Quarter Operating Results 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4
(Date:4/18/2014)... wildlife while feeding a world population predicted to ... holistic approach to conservation that considers human-altered landscapes ... Wildlife and the natural habitat that supports it ... world where at least three-quarters of the land ... rest is vulnerable to human-caused impacts such as ...
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/17/2014)... COLUMBIA, Mo. April 17 In the most densely ... States, forests reflect two centuries of human needs, values ... logging and clearing forests for agriculture and development, have ... today, a U.S. Forest Service study reports. , The ... forest conditions and management needs in the Northern United ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... channel has shown that a carpet of freeze-dried microbes that ... after water was diverted into it, said a University of ... resilience of life in the harsh polar environment, where temperatures ... melt water flows for only five to 12 weeks annually, ...
... showed that a fruit fly gene is crucial for ... how the transformation initially proceeds. Understanding this process in ... teenagers. , When the DHR4 gene is disabled, fruit ... to a sexually active adult. It is the first ...
... link between two biochemical pathways that plants use to ... believed worked independently of each other. , Knowing how ... researchers breed plants that can better resist a variety ... and an assistant professor of horticulture and crop science ...
Cached Biology News:Freeze-dried mats of microbes awaken in Antarctic streambed 2Freeze-dried mats of microbes awaken in Antarctic streambed 3Scientists find a maturity gene in fly 2Scientists find a maturity gene in fly 3Scientists find a maturity gene in fly 4Study: Plants use dual defense system to fight pathogens 2
...
... Sample Preparation for Membrane Proteins ,Contains ... membrane,protein extracts for 2-D gel analysis ... Extraction Kit , (contains sufficient ... a packed cell weight of 10 mg ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
... Amplifluor UniPrimer-fluorescein is a hairpin primer ... pair (fluorescein and non-fluorescent quencher) and ... The UniPrimer is identical to the ... Detection System (S7901) and is provided ...
Biology Products: